Aspect Partners’s Novo Nordisk NVO Stock Holding History

Aspect Partners’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$6.37K	Buy	168 +2	+1%	+$92	﹤0.01%	343
2026 Q2	$7.96K	Buy	166 +6	+4%	+$258	﹤0.01%	330
2026 Q1	$5.88K	Buy	160 +15	+10%	+$711	﹤0.01%	338
2025 Q4	$7.38K	Buy	145 +12	+9%	+$614	﹤0.01%	314
2025 Q3	$7.38K	Buy	133 +70	+111%	+$4.1K	﹤0.01%	354
2025 Q2	$4.35K	Buy	63 +39	+163%	+$2.65K	﹤0.01%	387
2025 Q1	$1.67K	Buy	24 +19	+380%	+$1.57K	﹤0.01%	466
2024 Q4	$429	Buy	+5	New	+$541	﹤0.01%	561

Other funds holding NVO

Saratoga Research & Investment Management Saratoga, California $1.82B AUM 11.8% 1-Year Est. Return

Euro Pacific Asset Management Dorado, Puerto Rico $1.22B AUM 22.48% 1-Year Est. Return

Nichols & Pratt Advisers Boston, Massachusetts $1.68B AUM 20.22% 1-Year Est. Return

Corda Investment Management Houston, Texas $1.52B AUM 30.53% 1-Year Est. Return

GuoLine Advisory Singapore $1.16B AUM 31.35% 1-Year Est. Return

QV Investors Calgary, Alberta, Canada $1.36B AUM 20.86% 1-Year Est. Return

Cantor Fitzgerald Investment Advisors New York $1.81B AUM 23.74% 1-Year Est. Return

Penbrook Management New York $169M AUM 32.52% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Viking Fund Management Minot, North Dakota $1.14B AUM 32.65% 1-Year Est. Return

Aspect Partners's NVO Position: Q3 2026 in Review

Aspect Partners increased its Novo Nordisk (NVO) stake by 1.2% in Q3 2026, buying an estimated $92 and bringing the position to 168 shares worth $6.37K. The position accounts for ﹤0.01% of the portfolio, ranked #343.

Aspect Partners first reported a position in NVO in Q4 2024 and has held it in 8 quarters since. The position peaked at $7.96K in Q2 2026. 338 funds tracked by Wall St. Rank hold NVO as of Q3 2026.

Aspect Partners held 168 shares of Novo Nordisk worth $6.37K as of Q3 2026.
Aspect Partners bought 2 Novo Nordisk shares in Q3 2026, an estimated $92.
Novo Nordisk made up ﹤0.01% of Aspect Partners's portfolio in Q3 2026, its #343 holding.
Aspect Partners first reported a position in Novo Nordisk in Q4 2024 and has held it in 8 quarters since.
Aspect Partners's Novo Nordisk position peaked at $7.96K in Q2 2026.
338 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.

Based on Aspect Partners's 13F filing for Q3 2026, filed 20 Oct 2026.